FGD3

Across TCGA pan-cancer cohorts, FGD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FGD3 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FGD3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FGD3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where FGD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.816	0.447	<.001	28	view →
HNSC	OS	Quartile	III,IV	0.964	0.166	.024	19	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.017	8	view →
PDAC	OS	Quartile	III,IV	0.500	1.000	.040	7	view →
CCRCC	DFS	Median	All	0.857	0.975	.043	1	view →
LSCC	DFS	Quartile	All	0.815	0.369	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FGD3–LUAD (DFS)

Open the LUAD breakdown →